The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Pharmacy benefit managers started popping up in the late 1960s as providers of claims processing and administrative services ...

Adorned in a Santa suit in a photo posted to X, the Tesla founder indicates he’s taking one of the widely popular weight-loss ...

No one has ever known so much about healthy eating and been less successful at following her own advice.

Elon Musk is accomplishing some end-of-the-year goals. The tech billionaire has shared a photo showing off his impressive ...

Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

The world’s richest man has clashed with incoming Health and Human Services chief Robert F. Kennedy Jr. over the role ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk ... for GLP-1 medications varies and the financial impact of these coverage differences. Data Source: ...